GET THE APP

Prevention and treatment of Alzheimerand#8217;s disease and other neurodegenerative disorders by inhibition of protein misfolding and aggregation
..

Neurological Disorders

ISSN: 2329-6895

Open Access

Prevention and treatment of Alzheimer’s disease and other neurodegenerative disorders by inhibition of protein misfolding and aggregation


Joint Event on 14th World Summit on Alzheimer’s Disease, Dementia Care Research and Awareness & 6th World Summit on Heart, Stroke and Neurological Disorders

August 31- September 01, 2018 | Boston, USA

Martin Tolar

Alzheon Inc, USA

Keynote: J Neurol Disord

Abstract :

Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead AlzheimerÔ??s clinical candidate, ALZ-801, is a Phase 3-ready, first-in-class, small molecule oral inhibitor of amyloid aggregation and neurotoxicity Ô?? hallmarks of AlzheimerÔ??s disease. ALZ-801 is a novel prodrug that builds on the safety and efficacy profile of the active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 AlzheimerÔ??s patients. Our clinical expertise and technology platform is focused on developing drug candidates using a Precision Medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients. ALZ-801 is a novel, oral anti-amyloid drug candidate that is an optimized prodrug of tramiprosate, which has shown promising results in analyses of clinical data and therapeutic mechanism of action. This includes the discovery of its novel molecular mechanism of action blocking the formation of toxic amyloid oligomers1 associated with the development and progression of an AD. The clinical data for ALZ-801 and its active agent, tramiprosate, suggest long-term clinical efficacy in AD patients with the APOE4 genotype, along with a favorable safety profile. The initial Phase 3 program for ALZ-801 will focus on patients with the homozygous APOE4/4 genotype at the Mild stage of an AD, with the potential for future expansion to additional AlzheimerÔ??s populations. ALZ-801 received Fast Track designation by the U.S. Food and Drug Administration (FDA) in October 2017.

Biography :

Prior to founding Alzheon, Dr. Tolar has held executive positions in life sciences companies, where he has successfully established and grown new companies, business areas and product opportunities. Dr. Tolar served as President & CEO of Knome, Inc., he pioneered human genome interpretation systems and services for academic, pharmaceutical and clinical clients, as President & CEO at NormOxys, Inc., he built and financed the business for novel cancer therapeutics and as CSO and CBO at CoMentis, Inc., he built the first clinical beta-secretase inhibitor platform and negotiated a landmark deal for the program for $1.1 billion with Astellas Pharma in 2008. Dr. Tolar held a variety of clinical development and business leadership positions at Pfizer, was instrumental in a wide range of business transactions, including an acquisition of Rinat Neuroscience for $500 million in 2006 and directed programs through all stages of clinical development and FDA approvals including NDA filings.

E-mail: [email protected]

 

Journal Highlights

Google Scholar citation report
Citations: 937

Neurological Disorders received 937 citations as per Google Scholar report

Neurological Disorders peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward